About Us | Contact

Yessar Mufeed Hussain Investigator

The Spine Hospital Of Louisiana NPI1982852166
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$261,879.32
from 123 payments in the last 6 years

Total Cash or Cash Equivalent

$243,515.97
from 77 payments in the last 6 years

Total In-kind Items & Services

$18,363.35
from 46 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
02/26/2021 General (Non-Research) In-kind items and services Food and Beverage $19.50 Details
Payment from GENZYME CORPORATION
Payment Record ID 843648899
11/10/2021 General (Non-Research) In-kind items and services Food and Beverage $96.19 Details
Payment from Spark Therapeutics, Inc.
Payment Record ID 842131685
02/05/2021 General (Non-Research) In-kind items and services Food and Beverage $19.88 Details
Payment from Xeris Pharmaceuticals, Inc.
Payment Record ID 837427193
04/29/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $1540.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 828521761
01/12/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $1540.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 828521665
09/22/2021 Research Cash or cash equivalent $1000.00 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Paymment Research Study A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF TAK-079 IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
Clinical Trials Gov ID NCT04159805
Payment Record ID 816644911
05/12/2021 Research Cash or cash equivalent $2000.00 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Paymment Research Study A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF TAK-079 IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
Clinical Trials Gov ID NCT04159805
Payment Record ID 816644893
05/12/2021 Research Cash or cash equivalent $2000.00 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Paymment Research Study A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF TAK-079 IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
Clinical Trials Gov ID NCT04159805
Payment Record ID 816644883
04/01/2021 Research Cash or cash equivalent Biological $7500.00 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Paymment Research Study THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF HYQVIA/HYQVIA (IGI, 10% WITH RECOMBINANT HUMAN HYALURONIDASE (RHUPH20) ADMINISTERED SUBCUTANEOUSLY) FOR MAINTENANCE THERAPY TO PREVENT RELAPSE (EPOCH 1) AND GAMMAGARD LIQUID/KIOVIG (IMMUNOGLOBULIN G INTRAVENOUS (IGIV) 10% ADMINISTERED INTRAVENOUSLY) FOR THE TREATMENT OF CIDP (EPOCH 2)
Clinical Trials Gov ID NCT02549170
Payment Record ID 816644873
11/24/2021 Research Cash or cash equivalent $2931.60 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781386425
11/24/2021 Research Cash or cash equivalent $5800.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781386419
11/24/2021 Research Cash or cash equivalent $3410.75 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781386401
11/24/2021 Research Cash or cash equivalent $2706.65 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781386395
11/24/2021 Research Cash or cash equivalent $3302.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781386389
11/24/2021 Research Cash or cash equivalent $1272.50 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781386383
10/26/2021 Research Cash or cash equivalent $40.50 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386371
10/26/2021 Research Cash or cash equivalent $68.85 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386359
10/26/2021 Research Cash or cash equivalent $74.25 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386353
10/26/2021 Research Cash or cash equivalent $108.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386347
10/26/2021 Research Cash or cash equivalent $133.65 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386341
10/26/2021 Research Cash or cash equivalent $135.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386335
10/26/2021 Research Cash or cash equivalent $225.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386329
10/26/2021 Research Cash or cash equivalent $368.55 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386323
10/20/2021 Research Cash or cash equivalent $472.50 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386317
10/20/2021 Research Cash or cash equivalent $500.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386311
10/26/2021 Research Cash or cash equivalent $726.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386305
10/26/2021 Research Cash or cash equivalent $1491.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386299
10/26/2021 Research Cash or cash equivalent $1872.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386293
10/26/2021 Research Cash or cash equivalent $2462.14 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386287
10/26/2021 Research Cash or cash equivalent $2879.25 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386281
11/08/2021 Research Cash or cash equivalent $5988.60 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386275
10/26/2021 Research Cash or cash equivalent $8000.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781386269
10/14/2021 Research Cash or cash equivalent $14732.51 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781385933
10/14/2021 Research Cash or cash equivalent $2975.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781385923
07/15/2021 Research Cash or cash equivalent $26456.07 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781385917
05/27/2021 Research Cash or cash equivalent $50.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781385911
03/18/2021 Research Cash or cash equivalent $300.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781385899
01/14/2021 Research Cash or cash equivalent $38743.97 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis
Clinical Trials Gov ID NCT03920293
Payment Record ID 781385893
03/24/2021 Research Cash or cash equivalent $525.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385867
05/14/2021 Research Cash or cash equivalent $600.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385861
05/14/2021 Research Cash or cash equivalent $750.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385855
04/02/2021 Research Cash or cash equivalent $4792.50 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385827
02/04/2021 Research Cash or cash equivalent $7453.80 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385821
07/23/2021 Research Cash or cash equivalent $250.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385809
07/23/2021 Research Cash or cash equivalent $500.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385797
07/23/2021 Research Cash or cash equivalent $676.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385791
10/04/2021 Research Cash or cash equivalent $1215.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385785
07/07/2021 Research Cash or cash equivalent $2001.60 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385779
07/23/2021 Research Cash or cash equivalent $2475.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385773
08/11/2021 Research Cash or cash equivalent $5143.50 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385767
10/20/2021 Research Cash or cash equivalent $5800.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385761
07/12/2021 Research Cash or cash equivalent $8500.00 Details
Payment from Alexion Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials Gov ID NCT04248465
Payment Record ID 781385749
11/30/2020 General (Non-Research) In-kind items and services Education $59.50 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 750758371
07/22/2020 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $33411.13 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 750758369
12/10/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $3080.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 750758367
12/15/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $2695.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 750758365
10/22/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $3080.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 750758361
01/29/2020 General (Non-Research) Cash or cash equivalent Travel and Lodging $10.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 750758311
01/29/2020 General (Non-Research) Cash or cash equivalent Travel and Lodging $57.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 750758283
01/29/2020 General (Non-Research) Cash or cash equivalent Travel and Lodging $10.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 750758281
11/17/2020 General (Non-Research) In-kind items and services Food and Beverage $23.02 Details
Payment from Grifols USA, LLC
Payment Record ID 750423367
10/14/2020 General (Non-Research) In-kind items and services Food and Beverage $14.50 Details
Payment from GENZYME CORPORATION
Payment Record ID 744263291
01/10/2020 General (Non-Research) In-kind items and services Food and Beverage $13.95 Details
Payment from Strongbridge US INC.
Payment Record ID 735173785
02/19/2020 General (Non-Research) In-kind items and services Food and Beverage $18.71 Details
Payment from Allergan, Inc.
Payment Record ID 723239655
01/09/2020 General (Non-Research) In-kind items and services Food and Beverage $18.02 Details
Payment from Allergan, Inc.
Payment Record ID 723239653
11/02/2020 General (Non-Research) In-kind items and services Food and Beverage $12.78 Details
Payment from Avanir Pharmaceuticals, Inc.
Payment Record ID 722207195
04/18/2019 General (Non-Research) In-kind items and services Food and Beverage $20.03 Details
Payment from NuVasive, Inc.
Payment Record ID 705171361
10/31/2019 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8692.60 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571557
11/07/2019 General (Non-Research) In-kind items and services Travel and Lodging $156.44 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571543
11/06/2019 General (Non-Research) In-kind items and services Travel and Lodging $517.42 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571541
11/06/2019 General (Non-Research) In-kind items and services Travel and Lodging $167.72 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571539
10/03/2019 General (Non-Research) In-kind items and services Travel and Lodging $349.98 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571537
11/26/2019 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1775.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571535
06/22/2019 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $750.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571451
02/04/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $54.50 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571429
02/04/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $11.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571427
02/04/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $54.50 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571417
02/04/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $32.02 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571415
02/04/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $11.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571413
02/04/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $12.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571411
02/04/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $16.01 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571409
02/04/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $18.67 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571407
02/04/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $14.19 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571405
02/04/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $36.00 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571403
02/04/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $10.78 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571401
02/04/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $6.50 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571399
06/24/2019 General (Non-Research) In-kind items and services Travel and Lodging $229.91 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571397
06/23/2019 General (Non-Research) In-kind items and services Travel and Lodging $230.06 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571395
06/22/2019 General (Non-Research) In-kind items and services Travel and Lodging $230.02 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571393
06/22/2019 General (Non-Research) In-kind items and services Travel and Lodging $14534.06 Details
Payment from Alnylam Pharmaceuticals Inc.
Payment Record ID 701571391
10/16/2019 General (Non-Research) In-kind items and services Food and Beverage $17.76 Details
Payment from GENZYME CORPORATION
Payment Record ID 694195679
02/05/2019 General (Non-Research) In-kind items and services Food and Beverage $17.86 Details
Payment from Grifols USA, LLC
Payment Record ID 692608025
08/08/2019 General (Non-Research) In-kind items and services Food and Beverage $22.79 Details
Payment from Grifols USA, LLC
Payment Record ID 692593033
04/13/2019 General (Non-Research) Cash or cash equivalent Honoraria $4290.00 Details
Payment from CSL Behring
Payment Record ID 683878939
04/13/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $683.11 Details
Payment from CSL Behring
Payment Record ID 683878937
04/13/2019 General (Non-Research) In-kind items and services Travel and Lodging $270.07 Details
Payment from CSL Behring
Payment Record ID 683878935
04/13/2019 General (Non-Research) In-kind items and services Food and Beverage $168.20 Details
Payment from CSL Behring
Payment Record ID 683878933
04/13/2019 General (Non-Research) In-kind items and services Food and Beverage $103.06 Details
Payment from CSL Behring
Payment Record ID 683878931
04/13/2019 General (Non-Research) In-kind items and services Food and Beverage $76.45 Details
Payment from CSL Behring
Payment Record ID 683878929
04/13/2019 General (Non-Research) In-kind items and services Food and Beverage $45.99 Details
Payment from CSL Behring
Payment Record ID 683878927
04/13/2019 General (Non-Research) In-kind items and services Food and Beverage $33.83 Details
Payment from CSL Behring
Payment Record ID 683878925
04/13/2019 General (Non-Research) In-kind items and services Travel and Lodging $319.00 Details
Payment from CSL Behring
Payment Record ID 683878923
04/30/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $24.14 Details
Payment from CSL Behring
Payment Record ID 683878919
10/22/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $82.81 Details
Payment from CSL Behring
Payment Record ID 683878913
12/20/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $7.05 Details
Payment from CSL Behring
Payment Record ID 683878899
11/06/2019 General (Non-Research) In-kind items and services Education $55.00 Details
Payment from CSL Behring
Payment Record ID 683878891
04/25/2019 General (Non-Research) In-kind items and services Education $55.00 Details
Payment from CSL Behring
Payment Record ID 683878889
04/25/2019 General (Non-Research) In-kind items and services Education $55.00 Details
Payment from CSL Behring
Payment Record ID 683878887
04/25/2019 General (Non-Research) In-kind items and services Education $55.00 Details
Payment from CSL Behring
Payment Record ID 683878885
11/06/2019 General (Non-Research) In-kind items and services Education $55.00 Details
Payment from CSL Behring
Payment Record ID 683878883
04/25/2019 General (Non-Research) In-kind items and services Education $55.00 Details
Payment from CSL Behring
Payment Record ID 683878881
09/27/2019 General (Non-Research) In-kind items and services Food and Beverage $13.00 Details
Payment from Allergan Inc.
Payment Record ID 670566019
08/16/2019 General (Non-Research) In-kind items and services Food and Beverage $16.07 Details
Payment from Allergan Inc.
Payment Record ID 670566015
08/09/2019 General (Non-Research) In-kind items and services Food and Beverage $18.50 Details
Payment from Allergan Inc.
Payment Record ID 670566009
07/31/2019 General (Non-Research) In-kind items and services Food and Beverage $15.40 Details
Payment from Allergan Inc.
Payment Record ID 670566007
04/27/2019 General (Non-Research) In-kind items and services Food and Beverage $16.04 Details
Payment from Allergan Inc.
Payment Record ID 670566001
02/28/2019 General (Non-Research) In-kind items and services Food and Beverage $10.89 Details
Payment from Allergan Inc.
Payment Record ID 670565997
08/08/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $102.22 Details
Payment from Biogen, Inc.
Payment Record ID 660670829
12/07/2018 General (Non-Research) In-kind items and services Food and Beverage $14.05 Details
Payment from Allergan Inc.
Payment Record ID 594350303
05/01/2018 General (Non-Research) In-kind items and services Food and Beverage $14.39 Details
Payment from Allergan Inc.
Payment Record ID 594350281
03/06/2018 General (Non-Research) In-kind items and services Food and Beverage $66.42 Details
Payment from Alexion Pharmaceuticals, Inc.
Payment Record ID 569332205
08/24/2018 General (Non-Research) In-kind items and services Food and Beverage $20.19 Details
Payment from Alexion Pharmaceuticals, Inc.
Payment Record ID 569279111
05/27/2016 General (Non-Research) In-kind items and services Food and Beverage $21.70 Details
Payment from Allergan Inc.
Payment Record ID 381228060
;